UT Southwestern Study Uses Common Cold Virus For Gene Therapy To Treat Head And Neck Cancers

October 28, 1998

DALLAS -- Patients with advanced head and neck cancer that hasn't improved with surgery, radiation or chemotherapy may benefit from an experimental therapy available at UT Southwestern Medical Center at Dallas.

Physicians in the Department of Otorhinolaryngology have begun injecting a genetically altered adenovirus, one of the viruses that cause the common cold, directly into the tumors of patients with head and neck cancer in an attempt to kill the cancer cells but preserve normal ones.

The unconventional treatment has slowed tumor growth in studies involving cell cultures and a mouse model. Now UT Southwestern is one of a handful of sites nationwide trying to measure how well human tumors respond to the treatment. The findings will help researchers decide whether to expand the study to a more widespread clinical trial.

"For this study, we are treating head-and-neck-cancer patients who have really exhausted their other options," said Dr. Carol Bier-Laning, assistant professor of otorhinolaryngology. "The goal is to gather information for the future, though the patients may improve. We have seen patients who have little or no response to the treatment, and we have seen some results that are very encouraging."

The therapy is based on understanding the role of the p53 gene, a tumor suppressor that responds to damage in a cell's deoxyribonucleic acid (DNA) by activating either a pathway that halts cell division until the DNA damage has been repaired or a pathway to apoptosis, or cell suicide. But half of human cancers -- and the majority of head and neck cancers -- have mutated p53 genes that are ineffective.

"We inject the tumor with an adenovirus that contains p53 that has been genetically engineered so it cannot replicate," said Bier-Laning, a co-principal investigator for the study at UT Southwestern. "The virus spits DNA into the cell, and the cell takes it up and begins producing the p53 gene. The hypothesis is that if we give the cells normal p53, it will help control the cancer."

Although the treatment may be effective against other cancers, this trial involves only head and neck cancers, which are easy to access for injection.

Patients who qualify for the study will receive three injections of the virus in three days, followed by a 28-day rest, then another round of injections. Patients whose tumors stabilize or grow less than 25 percent may be eligible for up to four more cycles of injections.

"This treatment isn't yet a mainline therapy to cure the cancer, but maybe it will return the cancer cells to a more normal profile," Bier-Laning said. "It's exciting because this gene therapy gives us a fourth prong in our fight against head and neck cancer."

Introgen Therapeutics, Inc., developed and manufactures the genetically engineered adenovirus used in the study. Introgen collaborates with RhÙne-Poulenc Rorer Pharmaceuticals for the clinical development and commercialization of the p53 drug. Others from UT Southwestern's head-and-neck-surgery unit involved in the study are Dr. John Truelson, associate professor of otorhinolaryngology and the study's co-principal investigator; Dr. Robert Sinard, assistant professor of otorhinolaryngology; and research nurse Sandra Neal.
-end-


UT Southwestern Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.